Serum adropin as a potential renoprotective factor in diabetic kidney disease: evidence from a Chinese elderly cohort and an experimental mouse model - Scorecard - MDSpire
Advertisement
Serum adropin as a potential renoprotective factor in diabetic kidney disease: evidence from a Chinese elderly cohort and an experimental mouse model
Clinical Scorecard: Serum Adropin as a Potential Protective Agent Against Diabetic Kidney Disease: Insights from an Elderly Chinese Population and an Animal Model Study
At a Glance
Category
Detail
Condition
Diabetic Kidney Disease (DKD)
Key Mechanisms
Involvement of adropin in metabolic regulation, vascular biology, and attenuation of oxidative stress and inflammation.
Target Population
Elderly individuals with diabetes in a community-based cohort in Xiamen, China.
Care Setting
Community-based health examinations.
Key Highlights
Higher serum adropin levels are inversely associated with prevalent DKD.
Increased baseline adropin correlates with lower risk of incident DKD.
Adropin treatment in mice improved renal injury indicators.
Guideline-Based Recommendations
Diagnosis
Evaluate serum adropin levels in patients with diabetes for risk assessment of DKD.
Management
Consider adropin as a potential therapeutic target in DKD.
Monitoring & Follow-up
Monitor serum adropin levels longitudinally in patients at risk for DKD.
Risks
Higher incidence of DKD associated with lower serum adropin levels.
Patient & Prescribing Data
Elderly individuals with diabetes, particularly those at risk for DKD.
Adropin administration may mitigate renal injury in DKD.
Clinical Best Practices
Integrate serum adropin measurement in routine assessments for patients with diabetes.
Utilize community-based cohort data to inform DKD risk management strategies.
